Change in Antithyroglobulin Antibody Levels is a Good Predictor of Responses to Therapy in Antithyroglobulin Antibody-Positive Pediatric Papillary Thyroid Carcinoma Patients
Table 2
Univariate analysis clinicopathologic factors associated with responses to therapy.
No. of patients
Acceptable
Unacceptable
Age at diagnosis of DTC
≤15
13 (27.08%)
7 (25.00%)
6 (30.00%)
0.701
>15
35 (73.93%)
21 (75.00%)
14 (70.00%)
Sex
Female
44 (91.67%)
25 (89.29%)
19 (95.00%)
0.860
Male
4 (8.3%)
3 (10.71%)
1 (5.00%)
Number of thyroid surgeries
1
40 (83.33%)
24 (85.71%)
16 (80.00%)
0.896
>1
8 (16.67%)
4 (14.29%)
4 (20.00%)
Tumor diameter (cm)
≤2
24 (50.0%)
15 (53.57%)
9 (45.00%)
0.807
>2, ≤4
16 (33.33%)
9 (32.14%)
7 (35.00%)
≥4
8 (16.67%)
4 (14.27%)
4 (10.00%)
Multiplicity
Single
26 (54.17%)
16 (57.14%)
10 (50.00%)
0.624
Multiple
22 (45.83%)
12 (42.86%)
10 (50.00%)
Extra-thyroidal extension
No
31 (64.58%)
24 (85.71%)
7 (35.00%)
＜0.001
Minimal/gross
17 (35.42%)
4 (14.28%)
13 (65.00%)
N stage
N0 or Nx
4 (8.33%)
2 (7.14%)
2 (10.00%)
0.536
N1a
11 (22.92%)
8 (28.57%)
3 (15.00%)
N1b
33 (68.75%)
18 (64.29%)
15 (75.00%)
Initial risk stratification
Low/intermediate
26 (54.17%)
22 (78.57%)
4 (20.00%)
＜0.001
High
22 (45.83%)
32 (21.43%)
16 (80.00%)
With LT
No
25 (52.08%)
13 (46.43%)
12 (60.00%)
0.353
Yes
23 (47.92%)
15 (53.57%)
8 (40.00%)
Number of courses for 131I therapy
1
40 (83.33%)
24 (85.71%)
16 (80.00%)
0.896
>1
8 (16.67%)
4 (14.29%)
4 (20.00%)
Cumulative dose of 131I activities (mCi)
≤100
40 (83.33%)
24 (85.71%)
13 (65.00%)
0.182
>100
8 (16.67%)
4 (14.29%)
7 (14.29%)
sTg (ng/ml)
<1
32 (66.67%)
19 (67.86%)
13 (65.00%)
0.836
≥1
18 (33.33%)
9 (32.14%)
7 (35.00%)
sTgAb (IU/ml)
<500
27 (56.25%)
19 (67.86%)
8 (40.00%)
0.055
≥500
21 (43.75%)
9 (32.14%)
12 (60.00%)
Suppressed Tg at first follow-up after RAI therapy
